Market Research Logo

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2018

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2018, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline landscape.

Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 12, 39, 24, 1, 88, 24 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 1 molecules, respectively.

Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Chronic Obstructive Pulmonary Disease (COPD) - Overview
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development
Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment
Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development
Chronic Obstructive Pulmonary Disease (COPD) - Drug Profiles
Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects
Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products
Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones
Appendix
List of Tables
Table 1: Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2018
Table 2: Number of Products under Development by Companies, H1 2018
Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Table 7: Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Table 8: Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Table 9: Number of Products under Development by Universities/Institutes, H1 2018
Table 10: Products under Development by Companies, H1 2018
Table 11: Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Table 12: Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Table 13: Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Table 14: Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Table 15: Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Table 16: Products under Development by Companies, H1 2018 (Contd..6), H1 2018
Table 17: Products under Development by Companies, H1 2018 (Contd..7), H1 2018
Table 18: Products under Development by Companies, H1 2018 (Contd..8), H1 2018
Table 19: Products under Development by Companies, H1 2018 (Contd..9), H1 2018
Table 20: Products under Development by Companies, H1 2018 (Contd..10), H1 2018
Table 21: Products under Development by Universities/Institutes, H1 2018
Table 22: Number of Products by Stage and Target, H1 2018
Table 23: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Table 24: Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018
Table 25: Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018
Table 26: Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018
Table 27: Number of Products by Stage and Mechanism of Action, H1 2018
Table 28: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Table 29: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018
Table 30: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018
Table 31: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018
Table 32: Number of Products by Stage and Route of Administration, H1 2018
Table 33: Number of Products by Stage and Molecule Type, H1 2018
Table 34: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB Science SA, H1 2018
Table 35: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ache Laboratorios Farmaceuticos SA, H1 2018
Table 36: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Achillion Pharmaceuticals Inc, H1 2018
Table 37: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals Corp, H1 2018
Table 38: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H1 2018
Table 39: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H1 2018
Table 40: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinaire Therapeutics LLC, H1 2018
Table 41: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinky Biopharma, H1 2018
Table 42: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angiocrine Bioscience Inc, H1 2018
Table 43: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angion Biomedica Corp, H1 2018
Table 44: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by apceth Biopharma GmbH, H1 2018
Table 45: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Arch Biopartners Inc, H1 2018
Table 46: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aridis Pharmaceuticals LLC, H1 2018
Table 47: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Astellas Pharma Inc, H1 2018
Table 48: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AstraZeneca Plc, H1 2018
Table 49: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bayer AG, H1 2018
Table 50: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bioblue Technologies Inc, H1 2018
Table 51: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bioneer Corp, H1 2018
Table 52: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Table 53: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by C4X Discovery Holdings PLC, H1 2018
Table 54: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Carolus Therapeutics Inc, H1 2018
Table 55: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cellular Biomedicine Group Inc, H1 2018
Table 56: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Celon Pharma SA, H1 2018
Table 57: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Chiesi Farmaceutici SpA, H1 2018
Table 58: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by China Resources Pharmaceutical Group Ltd, H1 2018
Table 59: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cipla Ltd, H1 2018
Table 60: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Circassia Pharmaceuticals Plc, H1 2018
Table 61: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by CSL Ltd, H1 2018
Table 62: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cytokinetics Inc, H1 2018
Table 63: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2018
Table 64: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Table 65: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Diffusion Pharmaceuticals Inc, H1 2018
Table 66: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Domainex Ltd, H1 2018
Table 67: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Enterprise Therapeutics Ltd, H1 2018
Table 68: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Errant Gene Therapeutics LLC, H1 2018
Table 69: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Evaxion Biotech ApS, H1 2018
Table 70: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Galapagos NV, H1 2018
Table 71: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Gilead Sciences Inc, H1 2018
Table 72: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by GlaxoSmithKline Plc, H1 2018
Table 73: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2018
List of Figures
Figure 1: Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2018
Figure 2: Number of Products under Development by Companies, H1 2018
Figure 3: Number of Products under Development by Universities/Institutes, H1 2018
Figure 4: Number of Products by Top 10 Targets, H1 2018
Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018
Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Figure 10: Number of Products by Top 10 Molecule Types, H1 2018
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report